/VNDA
VNDA Stock - Vanda Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$6.75+1.20%
+$0.08 (+1.20%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+63.0%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VNDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.68 – $6.82
TARGET (TP)$11.00
STOP LOSS$6.21
RISK/REWARD1:7.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.69
52W High$7.05
52W Low$3.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $198.77M | $192.64M | $254.38M | $268.68M | $248.17M |
| Gross Profit | $187.46M | $177.84M | $230.10M | $243.05M | $224.80M |
| Gross Margin | 94.3% | 92.3% | 90.5% | 90.5% | 90.6% |
| Operating Income | $-40,660,000 | $-13,952,000 | $6.33M | $42.16M | $27.24M |
| Net Income | $-18,900,000 | $2.51M | $6.28M | $33.15M | $23.34M |
| Net Margin | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% |
| EPS | $-0.32 | $0.04 | $0.11 | $0.60 | $0.43 |
Company Overview
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$13
Average Target
↑ 97.5% Upside
Now
$11
Low
$13
Average
$18
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 5th 2025 | B. Riley Securities | Initiation | Buy | $11 |
| October 31st 2024 | H.C. Wainwright | Initiation | Buy | $18 |
| July 11th 2024 | Cantor Fitzgerald | Initiation | Overweight | $11 |
Earnings History & Surprises
VNDABeat Rate
59%
Last 17 quarters
Avg Surprise
-50.8%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.38
Q4 2025
EPS Surprise History
Q1 24
+55.6%
$-0.04vs$-0.09
Q2 24
-240.0%
$-0.07vs$0.05
Q3 24
+61.9%
$-0.08vs$-0.21
Q4 24
+47.1%
$-0.09vs$-0.17
Q1 25
+42.9%
$-0.08vs$-0.14
Q2 25
+9.1%
$-0.50vs$-0.55
Q3 25
-35.3%
$-0.46vs$-0.34
Q4 25
-22.6%
$-0.38vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-1.45 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.31 | $-0.38 | -22.6% | ✗ MISS |
Q3 2025 | Jul 31, 2025 | $-0.34 | $-0.46 | -35.3% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.55 | $-0.50 | +9.1% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.21 | $-0.08 | +61.9% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.05 | $-0.07 | -240.0% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $-0.09 | $-0.04 | +55.6% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $-0.13 | $0.03 | +123.1% | ✓ BEAT |
Q2 2023 | May 3, 2023 | — | $0.06 | — | — |
Q1 2023 | Feb 8, 2023 | $0.08 | $0.12 | +50.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.09 | $0.06 | -33.3% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.11 | $0.05 | -54.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.01 | $-0.11 | -1000.0% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $0.09 | $0.12 | +33.3% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.18 | $0.14 | -22.2% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $0.14 | $0.17 | +21.4% | ✓ BEAT |
Latest News
Vanda Pharmaceuticals Submitted An FDA Biologics License Application For Imsidolimab For Generalized Pustular Psoriasis
📈 PositiveBenzinga•Dec 15, 2025, 12:14 PM
Market-Moving News for December 5th
➖ NeutralBenzinga•Dec 5, 2025, 12:24 PM•Also: ,
Vanda jumps as FDA lifts tradipitant partial clinical hold
📈 PositiveSeeking Alpha•Dec 4, 2025, 10:51 PM
Vanda Pharmaceuticals shares are trading higher after the company announced that the FDA lifted its partial clinical hold on protocol VP-VLY-686-3403.
📈 PositiveBenzinga•Dec 4, 2025, 09:36 PM
Vanda Pharma Announces FDA Has Lifted The Partial Hold On Tradipitant, Clearing Path For Expanded Motion-Sickness Studies Ahead Of Dec. 30 PDUFA Date
📈 PositiveBenzinga•Dec 4, 2025, 09:22 PM
Vanda Pharmaceuticals Says FDA Extends Tradipitant Partial Clinical Hold Re-Review To December 5 2025 As Motion Sickness NDA Review And Labeling Discussions Continue Toward December 30 2025 PDUFA Date
➖ NeutralBenzinga•Nov 28, 2025, 12:02 PM
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 19, 2025, 11:52 AM•Also:
Vanda Pharmaceuticals Option Alert: Dec 19 $6 Calls At The Ask: 2499 @ $0.4 Vs 572 OI; Ref=$5.295
📈 PositiveBenzinga•Nov 18, 2025, 05:24 PM
Vanda Pharmaceuticals shares are trading higher after the company reported that tradipitant lowered GLP 1 induced nausea and vomiting in adult participants.
📈 PositiveBenzinga•Nov 18, 2025, 03:24 PM
Reported Earlier, Vanda Reports Tradipitant Significantly Reduces GLP 1 Induced Nausea And Vomiting Strengthening Role As Adjunct In Rapidly Expanding $50B Plus Market
📈 PositiveBenzinga•Nov 18, 2025, 07:21 AM
B. Riley Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $11
📈 PositiveBenzinga•Nov 5, 2025, 11:22 AM
Vanda Pharmaceuticals shares are trading lower. Cantor Fitzgerald lowered its price target on the stock from $13 to $11.
📉 NegativeBenzinga•Oct 30, 2025, 03:34 PM
Cantor Fitzgerald Maintains Overweight on Vanda Pharmaceuticals, Lowers Price Target to $11
➖ NeutralBenzinga•Oct 30, 2025, 01:48 PM
Vanda Pharmaceuticals shares are trading lower after the company reported mixed Q3 financial results and narrowed its FY25 sales guidance.
📉 NegativeBenzinga•Oct 29, 2025, 08:41 PM
Vanda Pharmaceuticals Narrows FY2025 Sales Guidance from $210.000M-$250.000M to $210.000M-$230.000M vs $224.977M Est
📉 NegativeBenzinga•Oct 29, 2025, 08:02 PM
Vanda Pharma Q3 EPS $(0.38) Beats $(0.45) Estimate, Sales $56.258M Miss $58.733M Estimate
➖ NeutralBenzinga•Oct 29, 2025, 08:02 PM
Vanda Pharmaceuticals Agrees On A Collaborative Framework With The FDA For The Resolution Of Certain Disputes Regarding Hetlioz And Tradipitant
📈 PositiveBenzinga•Oct 1, 2025, 09:08 PM
Vanda Pharmaceuticals Announced The Publication Of An Article Titled "Melatonin Agonist Tasimelteon Improves Sleep In Patients With Primary Insomnia: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial" In PLOS One, A Leading Open-Access Journal
📈 PositiveBenzinga•Sep 25, 2025, 12:08 PM
Vanda Pharmaceuticals Receives FDA Orphan Drug Designation For VGT-1849B A Peptide Nucleic Acid-Based Candidate In Polycythemia Vera
📈 PositiveBenzinga•Aug 28, 2025, 11:04 AM•Also:
Vanda Pharmaceuticals Asked Martin Makary To Review The Decision Made By Jacqueline Corrigan-Curay, The Departing Director Of The FDA's Center For Drug Evaluation And Research Days Before Her Retirement That Upholds An Office Of Generic Drugs Decision To Approve Two Generic Versions Of Hetlioz
📉 NegativeBenzinga•Aug 21, 2025, 08:46 PM
Frequently Asked Questions about VNDA
What is VNDA's current stock price?
Vanda Pharmaceuticals Inc. (VNDA) is currently trading at $6.75 per share. The stock has moved +1.20% today.
What is the analyst price target for VNDA?
The average analyst price target for VNDA is $11.00, based on 1 analyst.
What sector is Vanda Pharmaceuticals Inc. in?
Vanda Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VNDA's market cap?
Vanda Pharmaceuticals Inc. has a market capitalization of $0.40 billion, making it a small-cap company.
Does VNDA pay dividends?
No, Vanda Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to VNDA for comparison